World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
28273
World Ranking
18287
National Ranking
232

Denis Larsimont publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Denis Larsimont sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 591 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Denis Larsimont D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Denis Larsimont sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Denis Larsimont is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on Oncology and Cancer Research. Additional subfields include Radiology, Nuclear Medicine and Imaging, Molecular Biology, and Pulmonary and Respiratory Medicine.

The main topics addressed in their work cover Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers, Radiomics and Machine Learning in Medical Imaging, Cancer Cells and Metastasis, Breast Lesions and Carcinomas, and Immunotherapy and Immune Responses.

Frequent venues where Larsimont's research is published include:

  • Cancer Research
  • European Journal of Surgical Oncology
  • Annals of Oncology
  • npj Breast Cancer
  • The Journal of Pathology

Notable recent papers authored or co-authored by Denis Larsimont include:

  • The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice, 2020, The Journal of Pathology
  • Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer, 2020, npj Breast Cancer
  • Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity, 2021, Journal of Clinical Investigation
  • Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells, 2020, Nature Communications
  • Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights, 2022, British Journal of Cancer

Denis Larsimont frequently collaborates with several co-authors, including Christos Sotiriou, Ligia Craciun, Françoise Rothé, David Venet, and Isabelle Veys. The frequency of collaboration with these co-authors ranges from 30 to over 50 joint works.

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

    Christos Sotiriou;Pratyaksha Wirapati;Sherene Loi;Adrian Harris

  • Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

    E de Azambuja;F Cardoso;G de Castro;M Colozza

  • CD4+ follicular helper T cell infiltration predicts breast cancer survival

    Chunyan Gu-Trantien;Sherene Loi;Soizic Garaud;Carole Equeter

  • Identification of molecular apocrine breast tumours by microarray analysis

    Pierre Farmer;Herve Bonnefoi;Véronique Becette;Michele Tubiana-Hulin

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.

    Christine Desmedt;Benjamin Haibe-Kains;Pratyaksha Wirapati;Marc Buyse

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Identification of molecular apocrine breast tumours by microarray analysis

    P Farmer;H Bonnefoi;V Becette;M Tubiana-Hulin

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing

    Lucy R. Yates;Moritz Gerstung;Stian Knappskog;Christine Desmedt

  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

    Mitch Dowsett;Craig Allred;Jill Knox;Emma Quinn

  • High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

    Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  • Chromogenic in Situ Hybridization: A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples

    Minna Tanner;David Gancberg;Angelo Di Leo;Denis Larsimont

  • Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

    Y S Ju;L B Alexandrov;M Gerstung;I Martincorena

  • PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

    Sherene Loi;Sherene Loi;Sherene Loi;Benjamin Haibe-Kains;Samira Majjaj;Francoise Lallemand

  • HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil

    Angelo Di Leo;David Gancberg;Denis Larsimont;Minna Tanner

  • Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

    D. Gancberg;A. Di Leo;F. Cardoso;G. Rouas

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

Frequent Co-Authors

Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Martine Piccart
Martine Piccart Université Libre de Bruxelles
Roberto Salgado
Roberto Salgado Peter MacCallum Cancer Centre
Karen Willard-Gallo
Karen Willard-Gallo Institut Jules Bordet
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Marianne Paesmans
Marianne Paesmans Université Libre de Bruxelles
Stefan Michiels
Stefan Michiels University of Paris-Saclay
Benjamin Haibe-Kains
Benjamin Haibe-Kains Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to various healthcare careers and online degree options. For students looking to enter nursing, it’s helpful to consider what is the easiest nursing school to get into, especially if you’re concerned about competitive admissions or GPA requirements. Additionally, some programs are accessible even if you haven’t completed the TEAS or HESI exams—learn more by researching nursing schools that don't require teas or hesi.

If you’re interested in healthcare but prefer non-clinical roles, an in-demand option is online medical billing and coding with financial aid. This field offers remote work flexibility and a quick path to employment.

For those considering management, pursuing a healthcare administration degree is also a strategic choice. Accelerated online programs can help you advance quickly into leadership roles within healthcare systems.

Each of these pathways offers unique entry points and career opportunities, making the healthcare field diverse and accessible to a wide variety of students.

Best Scientists Citing Denis Larsimont

Trending Scientists

Recently Published Articles